Journal of Crohn s and Colitis · 2023 · 62 citations · 45 references
Life SciencesClinical SciencesImmunologyImmunoregulationInflammationNeuroimmunologyAutoimmune DiseasesAutoimmune InflammationAutoimmune Rheumatic DiseasesImmune-mediated Inflammatory DiseasesInflammatory ArthritisRheumatoid ArthritisImmunoregulatory SignalingInflammatory Bowel Disease TherapyInflammatory ReflexNeuroimmune ModulationRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyVagus Nerve Anti-inflammatory PathwayVagus Nerve Immune Signaling
BACKGROUND AND AIMS: Crohn's disease [CD] is a debilitating, inflammatory condition affecting the gastrointestinal tract. There is no cure and sustained clinical and endoscopic remission is achieved by fewer than half of patients with current therapies. The immunoregulatory function of the vagus nerve, the 'inflammatory reflex', has been established in patients with rheumatoid arthritis and biologic-naive CD. The aim of this study was to explore the safety and efficacy of vagus nerve stimulation in patients with treatment-refractory CD, in a 16-week, open-label, multicentre, clinical trial. METHODS: A vagus nerve stimulator was implanted in 17 biologic drug-refractory patients with moderately to severely active CD. One patient exited the study pre-treatment, and 16 patients were treated with vagus nerve stimulation [4/16 receiving concomitant biologics] during 16 weeks of induction and 24 months of maintenance treatment. Endpoints included clinical improvement, patient-reported outcomes, objective measures of inflammation [endoscopic/molecular], and safety. RESULTS: There was a statistically significant and clinically meaningful decrease in CD Activity Index at Week 16 [mean ± SD: -86.2 ± 92.8, p = 0.003], a significant decrease in faecal calprotectin [-2923 ± 4104, p = 0.015], a decrease in mucosal inflammation in 11/15 patients with paired endoscopies [-2.1 ± 1.7, p = 0.23], and a decrease in serum tumour necrosis factor and interferon-γ [46-52%]. Two quality-of-life indices improved in 7/11 patients treated without biologics. There was one study-related severe adverse event: a postoperative infection requiring device explantation. CONCLUSIONS: Neuroimmune modulation via vagus nerve stimulation was generally safe and well tolerated, with a clinically meaningful reduction in clinical disease activity associated with endoscopic improvement, reduced levels of faecal calprotectin and serum cytokines, and improved quality of life.
45
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
L. V. Borovikova, Svetlana Ivanova, Minghuang Zhang et al. · Nature · 2000 · 4.2K citations
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Hong Wang, Man Yu, Mahendar Ochani et al. · Nature · 2002 · 3.2K citations
Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit
Mauricio Rosas‐Ballina, Peder S. Olofsson, Mahendar Ochani et al. · Science · 2011 · 1.5K citations · Full text
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Hong Wang, Hong Liao, Mahendar Ochani et al. · Nature Medicine · 2004 · 1.2K citations